Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.40 |
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.40 |
| ▸ | TET3 | O43151 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29199307 | 0.97 | OR51E2 (0.43) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| SCHEMBL14783031 | 0.77 | HTT (0.35) | OR51E2TET2HTTTSHR | |
| SCHEMBL18634509 | 0.76 | TET2 (0.50) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| SCHEMBL14533958 | 0.76 | HTT (0.36) | HTT | |
| SCHEMBL15619373 | 0.76 | TET2 (0.50) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| SCHEMBL14533959 | 0.76 | HTT (0.36) | HTT | |
| SCHEMBL15717565 | 0.76 | HTT (0.36) | HTT | |
| SCHEMBL27576207 | 0.75 | OR51E2 (0.39) | OR51E2SMN1; SMN2TET2KDM4AKDM4C | |
| SCHEMBL19825149 | 0.74 | CHRM1 (0.38) | HTT | |
| SCHEMBL11873875 | 0.72 | OR51E2 (0.46) | OR51E2SMN1; SMN2TET2KDM4AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| JP-11322665-A | — | — | None | — | — | JP | disclosed |
| JP-11075889-A | — | — | None | — | — | JP | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | disclosed |
| JP-2003079392-A | METHOD FOR PRODUCING OPTICALLY ACTIVE α- TRIFLUOROMETHYLLACTIC ACID | MITSUBISHI RAYON CO LTD | 2003-03-18 | — | — | JP | disclosed |
| JP-H11322665-A | PURIFICATION OF OPTICALLY ACTIVE ALPHA-TRIFLUOROMETHYL LACTIC ACID | MITSUBISHI RAYON CO LTD | 1999-11-24 | — | — | JP | disclosed |
| JP-H1175889-A | PRODUCTION AND PURIFICATION OF OPTICALLY ACTIVE ALPHA-TRIFLUOROMETHYLLACTIC ACID AND ITS ENANTIOMER ESTER | MITSUBISHI RAYON CO LTD | 1999-03-23 | — | — | JP | disclosed |
| US-5180417-A | 4-((aryloxy)phenoxy)fluoroalkanoic acid derivatives and their herbicidal uses | DOWELANCO (US) | 1993-01-19 | — | — | US | disclosed |
| US-5118836-A | OPTICALLY ACTIVE FLUORINE-CONTAINING 3-HYDROXYBUTYRIC ACID ESTERS AND PROCESS FOR PRODUCING THE SAME | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1992-06-02 | — | — | US | disclosed |
| US-5032168-A | 4-((aryloxy)phenoxy)fluoroalkanoic acid derivatives and their herbicidal uses | DOWELANCO (US) | 1991-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | OR51E2 3583/4885SMN1; SMN2 3490/4885TET2 1928/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | OR51E2 3583/4885SMN1; SMN2 3490/4885TET2 1928/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | OR51E2 3583/4885SMN1; SMN2 3490/4885TET2 1928/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | OR51E2 3583/4885SMN1; SMN2 3490/4885TET2 1928/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | OR51E2 3133/4885SMN1; SMN2 994/4885TET2 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.